- Home
- VTYX
as 07-26-2024 4:00pm EST
Ventyx Biosciences Inc is a clinical-stage biopharmaceutical company focused on advancing new therapies for millions of patients living with inflammatory diseases and autoimmune disorders. The company is developing a pipeline of novel small-molecule product candidates to address a range of inflammatory diseases. Its product candidate VTX958 is an oral, selective clinical-stage tyrosine kinase type 2 (TYK2) inhibitor designed to inhibit TYK2 without detectable inhibition of other Janus kinase (JAK) isoforms, which avoids toxicities associated with broader JAK inhibition and, thus, other JAK inhibitors.
| Founded: | 2018 | Country: | United States |
| Employees: | N/A | City: | SAN DIEGO |
| Market Cap: | 193.9M | IPO Year: | 2021 |
| Target Price: | $18.67 | AVG Volume (30 days): | 1.0M |
| Analyst Decision: | Buy | Number of Analysts: | 9 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -3.24 | EPS Growth: | N/A |
| 52 Week Low/High: | $1.86 - $38.20 | Next Earning Date: | 08-08-2024 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Stock Insider Trading Activity of Ventyx Biosciences Inc. (VTYX)
| Name | Ticker | Relationship | Date | Transaction | Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Nuss John | VTYX | CHIEF SCIENTIFIC OFFICER | Apr 2 '24 | Sell | $5.40 | 1,651 | $8,921.01 | 264,998 | SEC Form 4 |
| Mohan Raju | VTYX | CEO AND PRESIDENT | Apr 2 '24 | Sell | $5.40 | 4,312 | $23,299.46 | 1,578,250 | SEC Form 4 |
| Krueger Christopher W | VTYX | CHIEF BUSINESS OFFICER | Apr 2 '24 | Sell | $5.40 | 1,651 | $8,921.34 | 284,999 | SEC Form 4 |
| Auster Martin | VTYX | CHIEF FINANCIAL OFFICER | Apr 2 '24 | Sell | $5.40 | 1,405 | $7,591.92 | 24,303 | SEC Form 4 |
| Nuss John | VTYX | Chief Scientific Officer | Dec 20 '23 | Sell | $2.12 | 17,628 | $37,334.34 | 262,118 | SEC Form 4 |
| Mohan Raju | VTYX | CEO and President | Dec 20 '23 | Sell | $2.12 | 58,860 | $124,659.59 | 1,570,719 | SEC Form 4 |
| Krueger Christopher W | VTYX | Chief Business Officer | Dec 20 '23 | Sell | $2.12 | 5,293 | $11,210.04 | 282,119 | SEC Form 4 |
Latest Ventyx Biosciences Inc. News
VTYX Breaking Stock News: Dive into VTYX Ticker-Specific Updates for Smart Investing
Simply Wall St.
20 days ago
Is Ventyx Biosciences (NASDAQ:VTYX) In A Good Position To Invest In Growth?
CNW Group
2 months ago
The Government of Canada invests over $3.3 million in nine grassroots, community projects to curb greenhouse gas emissions and fight climate change
GlobeNewswire
2 months ago
CONDITIONS FOR RIKSBANK AUCTIONS GOVERNMENT BONDS
GlobeNewswire
2 months ago
Onfolio Holdings Inc. To Acquire DDS Rank Business
GlobeNewswire
2 months ago
Thor Equities Group Advances Cross-Border Logistics Strategy with Key Acquisition
Investor's Business Daily
2 months ago
As Nvidia Teases Mega Milestone, This AI Stock Targets Early Breakout
PR Newswire
2 months ago
See's Candies® Launches New Scotchmallow® Littles
AFP
2 months ago
Biden announces $225 mn in new aid for Ukraine at Paris talks with Zelensky
Compare VTYX vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "VTYX Ventyx Biosciences Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.